TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03661996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine without epinephrine
Description: 15 mL lidocaine intra-articular injection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ElastoGel
Description: Cooling Device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ElastoGel
Description: Cooling Device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ElastoGel
Description: Cooling Device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ElastoGel
Description: Cooling Device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breg Ice Water Pump
Description: Cooling Device
Study: NCT03746743

Intervention type: DIAGNOSTIC_TEST
Intervention: score for neonatal sepsis
Description: score for neonatal sepsis to predict morbidity

Intervention type: DIAGNOSTIC_TEST
Intervention: score for neonatal sepsis
Description: score for neonatal sepsis to predict morbidity
Study: NCT03785457

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repetitive Trunk Extension
Description: Subjects will be asked to perform standing repetitive trunk extension at a rate of 10 per 45 seconds (Figure 2), repeated five times with 15-second rest breaks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sustained Trunk Extension
Description: Subjects will be asked to perform standing sustained trunk extension for 5 x 45 seconds with 15-second rest breaks.
Study: NCT04114851

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NoL
Description: NoL active
Study: NCT04639921

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: positive test followed by gluten-free diet
Description: DBPCFC with gluten

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: positive test followed by gluten-free diet
Description: DBPCFC with gluten

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00807521

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Single high dose bolus of dexamethasone before surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for dexamethasone
Study: NCT02519647

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal intubation with Gliderite
Description: Tracheal intubation with Gliderite

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tracheal intubation with S-guide
Description: Tracheal intubation with S-guide
Study: NCT00584701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Dose will start at 0.5 mg and may be increased throughout the course of the study if no adverse events occur
Study: NCT03659643

Intervention type: DIAGNOSTIC_TEST
Intervention: EEG with SPR analysis
Description: qEEG with SPR analysis was performed in group 1 during 2011-2013 and in group 2, the same procedure is performed.

Intervention type: DIAGNOSTIC_TEST
Intervention: EEG with SPR analysis
Description: qEEG with SPR analysis was performed in group 1 during 2011-2013 and in group 2, the same procedure is performed.
Study: NCT04639518

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preterm formulas with HMO
Description: Preterm infants will receive Stage 1 formula as soon as possible after birth until when 1.8 kg of body weight is achieved. Preterm infants will receive Stage 2 preterm formula from when 1.8 kg of body weight is achieved until 2 months after hospital discharge.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preterm formulas without HMO
Description: Preterm infants will receive Stage 1 formula as soon as possible after birth until when 1.8 kg of body weight is achieved. Preterm infants will receive Stage 2 preterm formula from when 1.8 kg of body weight is achieved until 2 months after hospital discharge.
Study: NCT01083147

Intervention type: DEVICE
Intervention: FORESEE HOME
Description: Home Monitoring
Study: NCT01989286

Intervention type: OTHER
Intervention: Assessment
Description: The posture, motor development and balance are going to be assessed.
Study: NCT04539119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: Participants will be given tenofovir 300mg (1 capsule) qd po two weeks before the first cycle of treatment. HBV DNA will be measured before each cycle of chemotherapy or immunotherapy. Tenofovir will be given until the copy count of HBV DNA drops below 1\*10\^3/L.
Study: NCT02449317

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bioimpedance guided
Description: bioelectrical impedance analysis guided hydration therapy : 7.5% Sodium bicarbonate 150 ml + 5% dextrose in water 850 ml IV in 6 hours rate was adjusted regarding to extracellular water/total body water~* extracellular water/total body water \< 0.36 : 4 ml/kg/hr~* extracellular water/total body water 0.36-0.4 : 2 ml/kg/hr~* extracellular water/total body water \> 0.4 : 1 ml/kg/hr

Intervention type: OTHER
Group type: OTHER
Intervention: standard hydration
Description: standard hydration : 7.5%Sodium bicarbonate 150 ml + 5% dextrose in water 850 ml IV 1 ml/kg/hr in 6 hours
Study: NCT03585153

Intervention type: OTHER
Intervention: Non-contrast magnetic resonance imaging
Description: subjects lie in an MRI machine (non-contrast) for 30 minutes while we take pictures of their pancreas

Intervention type: OTHER
Intervention: Non-contrast magnetic resonance imaging
Description: subjects lie in an MRI machine (non-contrast) for 30 minutes while we take pictures of their pancreas
Study: NCT04539119

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: Participants will be given entecavir 0.5 mg (1 capsule) qd po from two weeks before the first cycle of treatment until one year after the end of treatment. HBV DNA will be measured before each cycle of chemotherapy or immunotherapy. Entecavir will be given until one year after the end of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Participants will be given entecavir 0.5 mg (1 capsule) qd po from two weeks before the first cycle of treatment until one year after the end of treatment. HBV DNA will be measured before each cycle of chemotherapy or immunotherapy. Entecavir will be given until one year after the end of treatment.
Study: NCT04470219

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive support by RemindMe
Study: NCT02421900

Intervention type: OTHER
Intervention: radio-frequency catheter ablation of atrial fibrillation
Description: radio-frequency catheter ablation of atrial fibrillation
Study: NCT01701193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Alanyl/L-Glutamine
Description: Sterile solution of L-Alanyl-L-Glutamine, 400mg/mL in water for injection. It is dosed at 1g/kg of body weight and is instilled into the peritoneum at the time of surgery. The active ingredient, glutamine, is a conditionally essential amino acid component of nutritional supplements.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Alanyl/L-Glutamine
Description: Sterile solution of L-Alanyl-L-Glutamine, 400mg/mL in water for injection. It is dosed at 1g/kg of body weight and is instilled into the peritoneum at the time of surgery. The active ingredient, glutamine, is a conditionally essential amino acid component of nutritional supplements.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Physiologic saline
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Physiologic saline
Description: Placebo
Study: NCT04417192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib will be administered at a dose of 300mg as oral dose, twice a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered at a dose of 200mg as a 30-minutes IV infusion, Q3W (25 minutes to 40 minutes are acceptable).
Study: NCT01936181

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remicade (infliximab)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remicade (infliximab)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB2 (proposed biosimilar to infliximab)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB2 (proposed biosimilar to infliximab)
Study: NCT03308136

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 1ml of local anesthetics (1% Lidocaine) were injected into the subcutaneous layer.
Description: 1) In group A, 1ml of local anesthetics (1% Lidocaine) were injected into the subcutaneous layer.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 1ml of a local anesthetics (1% idocaine) are first injected into the subcutaneous layer, followed by 3~4ml of local anesthetics to the muscle layer along the expected needle pathway.
Description: 2) In group B, 1ml of a local anesthetics (1% Lidocaine) are first injected into the subcutaneous layer, followed by 3\~4ml of local anesthetics to the muscle layer along the expected needle pathway.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Lidocaine
Description: 1% Lidocaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% Lidocaine
Description: 1% Lidocaine
Study: NCT02763982

Intervention type: OTHER
Intervention: Physical evaluation

Intervention type: OTHER
Intervention: Physical evaluation

Intervention type: OTHER
Intervention: Physical evaluation
Study: NCT03070340

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Breast Magnetic Resonance Imaging (MRI)
Description: All women who are scheduled for a post-NAT breast MRI and mammogram will be asked to enroll in the study. The addition of contrast to the FFDM (CEDM) would be the only intervention.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Contrast Enhanced Mammography (CEDM)
Description: All women who are scheduled for a post-NAT breast MRI and mammogram will be asked to enroll in the study. The addition of contrast to the FFDM (CEDM) would be the only intervention.
Study: NCT00868725

Intervention type: OTHER
Intervention: no intervention, observation only
Description: Oral cavity will be imaged by a thermal camera.
Study: NCT03005223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-administration of DWC20155/DWC20156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-administration of DWC20155/DWC20156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC20163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC20163
Study: NCT02811016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide 200
Description: 200 µg inhaled at 7:00 a.m. and 7 p.m.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide 800
Description: 800 µg inhaled at 7:00 a.m. and 7 p.m.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Inhalation at 7:00 a.m. and 7 p.m.
Study: NCT03405272

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Anti-EGFR Monoclonal Antibody（SCT200）
Description: Experimental: recombinant anti-EGFR monoclonal antibody（SCT200） Recombinant Anti-EGFR Monoclonal Antibody（SCT200）. Initially, SCT200 6.0mg/kg will be administered at day 1 every week for a maximum of 6 cycles. After 6 cycles SCT200 8.0mg/kg will be administered at day 2 every weeks until disease progression.
Study: NCT04232098

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat to ankle
Description: Heat administered via hot water to ankle level

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat to calf
Description: Heat administered via hot water to calf level
Study: NCT04977518

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT04041752

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SOLID
Description: condition with a classical meal served using solid food items

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LIQUID_P
Description: condition with a liquid meal served using a powder solution

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LIQUID_L
Description: condition with a pre-prepared meal served using a liquid solution.
Study: NCT02459249

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy Lifestyle
Description: A physician and a nutritionist will be give recommendations for diet and exercise emphasizing the importance of a healthy lifestyle (suggesting moderate-intensity activity at least 150 minutes/week and to eat less sodium, fat, sugar, portions and calories). Verbal and written individualized recommendations from trained professionals (nutritionists, and physician) will be provided. Monthly sessions of at least 30 minutes covering diet, exercise, and behavior modifications were held. The first was a one-to-one meeting and was followed by group sessions based on behavioral counseling

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator (Treatment of Mexican Health Minister)
Description: General and unspecific recommendations of diet and physical activity for the metabolic syndrome treatment, given for a physician
Study: NCT02596022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CI-581a
Description: a 50 minute infusion 24 hours prior to cocaine self-administration session

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CI-581a
Description: a 50 minute infusion 24 hours prior to cocaine self-administration session

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CI-581b
Description: a 50 minute infusion 24 hours prior to cocaine self-administration session

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CI-581b
Description: a 50 minute infusion 24 hours prior to cocaine self-administration session
Study: NCT00642629

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: STA 5326 mesylate
Description: STA 5326 mesylate 100mg taken orally twice a day for 8 weeks with the option to continue at the same dose and frequency for an additional 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken orally twice a day for 8 weeks with the option to continue at the same dose and frequency for an additional 4 weeks.
Study: NCT02070120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Description: Patients assigned to the chemoresection group will receive 4 once weekly intravesical instillations of 40mg MMC as outpatients.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgical Management
Description: Patients in this group should be treated according to local practice. Surgical interventions may include transurethral resection (TUR) or ablation.
Study: NCT01200030

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: electrical stimulation with exercises
Description: electrical stimulation with exercises

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo stimulation with exercises
Description: placebo stimulation with exercises
Study: NCT00385853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTK787/ZK 222584
Description: Twice daily for each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Daily for each 28-day cycle

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: For 7 weeks beginning on day 5 of the first treatment cycle
Study: NCT03459703

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Time-Restricted Feeding
Description: Eat all meals between 7 am - 3 pm for an average of ≥6 days per week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Schedule
Description: Eat all meals over a 12-hour or longer period for an average of ≥6 days per week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Structured Weight Loss Program
Description: A structured weight loss program with physical activity recommendations and dietary counseling.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured Weight Loss Program
Description: A structured weight loss program with physical activity recommendations and dietary counseling.
Study: NCT02632786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NEOD001
Description: NEOD001 is a monoclonal antibody directed at soluble and insoluble light chain aggregates

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline Bag
Study: NCT00237484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction dose of (a) infliximab followed by combination of (b) pegylated interferon alfa-2b and (c) ribavirin
Description: 1. Powder for intravenous infusion (100 mg strength), intravenous, single dose of 5 mg/kg, at Day -7, prior to initiation of the following combination therapy:~2. powder for injection in vials or Redipen (80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks~3. 200 mg capsules, oral, dose of 800-1400 mg (weight based dosing as per PEGETRON Product Monograph), daily for up to 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination of (a) pegylated interferon alfa-2b and (b) ribavirin
Description: 1. Powder for injection in vials or Redipen (80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks~2. 200 mg capsules, oral, dose of 800-1400 mg (weight based dosing as per PEGETRON Product Monograph), daily for up to 48 weeks
Study: NCT03759613

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gait Analysis
Description: Gait Analysis: Gait analysis is not a routine assessment tool for upper extremity burn injuries. This analysis is an assessment method to estimate gait symmetry.~Restriction arm swing: Participants in group will be restricted for arm swing using a bandage. Thus, the reciprocal arm swing will be prevented.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Gait Analysis
Description: Gait Analysis: Gait analysis is not a routine assessment tool for upper extremity burn injuries. This analysis is an assessment method to estimate gait symmetry.~Restriction arm swing: Participants in group will be restricted for arm swing using a bandage. Thus, the reciprocal arm swing will be prevented.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait Analysis
Description: Gait Analysis: Gait analysis is not a routine assessment tool for upper extremity burn injuries. This analysis is an assessment method to estimate gait symmetry.~Restriction arm swing: Participants in group will be restricted for arm swing using a bandage. Thus, the reciprocal arm swing will be prevented.
Study: NCT02461875

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabergoline
Description: Patients receive cabergoline 0.5 mg p.o at bed time for 8 days starting on the day of HCG administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH antagonist rescue & cabergoline
Description: when the leading follicle reaches 16 mm, HP-uFSH is continued at daily dose of 75 IU/day till the day of HCG administration. Moreover, Gn RH agonist (triptorelin) is discontinued and GnRH antagonist (Cetrorelix acetate)0.25 mg S.C is administered daily till the day of HCG administration. Serum estradiol is measured daily and HCG (5,000 IU/I.M) is administered when serum estradiol level drops below 3500 pg/ml . Moreover, cabergoline 0.5 mg p.o is administered at bed time for 8 days starting on the day of HCG administration.
Study: NCT01588990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Participants will receive oxaliplatin 85 milligrams per square meter (mg/m\^2) IV infusion on Day 1 of every 2 weeks cycle during alternative Phase A treatment or 130 mg/m\^2 on Day 1 of every 3 weeks cycle during Phase A treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Participants will receive capecitabine 1000 mg/m\^2 per oral (PO) twice daily on Days 1-14 of 3 weeks cycle during Phase A treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Participants will receive 7.5 mg/kg IV infusion on Day 1 every 3 weeks (Phase A treatment) or 5 mg/kg IV on Day 1 every 2 weeks (Alternative Phase A treatment and Phase B).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Participants will receive leucovorin 400 mg/m\^2 IV on Day 1 every 2 weeks (Alternative Phase A treatment and Phase B). Investigators may elect to chose low dose of leucovorin (either 20 mg/m\^2 or 50 mg total dose).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluouracil
Description: Participants will receive 5-fluouracil loading dose of 400 mg/m\^2 IV on Day 1 followed by 2400 mg/m\^2 continuous IV infusion over 46 hours Day 1 (Alternative Phase A treatment and Phase B).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Participants will receive irinotecan 180 mg/m\^2 IV on Day 1 every 2 weeks during Phase B treatment.
Study: NCT00595829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL019
Description: XL019 capsules administered orally
Study: NCT04184362

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Empower Neuromodulation System Transcutaneous Electrical Nerve Stimulation
Description: Participants will self-administer treatment with the Empower device two times daily for two weeks. Participants will complete surveys over the two-week period to evaluate the effects of the Empower treatment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Empower Neuromodulation System Transcutaneous Electrical Nerve Stimulation
Description: Participants will self-administer treatment with the Empower device two times daily for two weeks. Participants will complete surveys over the two-week period to evaluate the effects of the Empower treatment.
Study: NCT01444729

Intervention type: DRUG
Intervention: Xiapex
Description: Xiapex administration will follow SMPC

Intervention type: PROCEDURE
Intervention: surgery
Description: Non-pharmacological treatment
Study: NCT03828110

Intervention type: DEVICE
Intervention: Robotic Assisted Gait Training (Lokomat)
Description: The RAGT treatment consisted of sessions lasting 45 minutes each performed with the commercially available Lokomat device. The same exercises were offered to the children with preset duration, speed, and difficulty. For all patients, the initial body-weight support was set at 50%, and was then gradually decreased according to the individual functional capacity. The guidance force was initially set to 100% for all children, and then gradually reduced.

Intervention type: PROCEDURE
Intervention: Physiotherapy
Description: The physiotherapic sessions aimed at strengthening the gluteus and quadriceps muscles, stretching the hip flexor and hamstrings muscles, increasing static balance, increasing dynamic balance, increasing functional abilities, improving ground gait and climbing stairs.